FIT HON TENG(06088.HK)上半年營收增6%至21.01億美元
格隆匯8月9日丨FIT HON TENG(06088.HK))公佈,截至2022年6月30日止六個月的營收為21.01億美元,同比增加6%;利潤為8500萬美元,同比增加963%,每股基本盈利為1.23美分。
公司的營收主要來自互連解決方案及其他產品銷售,而小部分營收來自模具部件、樣品銷售及其他銷售。在五個主要終端市場中,(1)智能手機終端市場產生的營收增加26.6%,(2)網絡設施終端市場產生的營收減少19.1%,(3)電腦及消費性電子終端市場產生的營收減少2.3%,(4)電動汽車終端市場產生的營收增加12.3%,及(5)系統終端產品市場產生的營收增加16.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.